News

Here's how four plans are using the management strategy to improve quality, reduce costs.

FDA this week approved a new indication for BioThrax to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease.

A new AARP report shows that the rapid rise in cost of specialty drugs exceeds median family income.

Traveling to Orlando for ASH 2015? Make the most out of your trip by attending these presentations. View the top 10.

In FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Here are five ways payers could help their members become more engaged in their health and provider-recommended treatment plan.

During the first half of 2016, UnitedHealth Group will determine to what extent it can to participate in the public exchange markets in 2017. Here's what this means for the industry.

The three trends that will carry into next year.

Most idiopathic pulmonary fibrosis patients have considerably impaired lung function and gastroesophageal reflux disease is the most common co-morbidity, according to initial results from the IPF-PRO Registry.

Is your plan making full use of its population health management systems? To help you find out, we asked two experts to weigh in.

As health insurers become increasingly more proactive and personalized in their interactions with individuals, they increase their ability to improve the cost and quality of healthcare while building loyalty in a competitive market.

FDA has approved cobimetinib (Cotellic, Genentech) to be used in combination with vemurafenib (Zelboraf) for the treatment of advanced melanoma.

We asked the Managed Healthcare Executive editorial advisory board, if you could change one thing about the healthcare industry what would it be? Here’s what they said.

The FDA accelerated approval for Darzalex injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or who are double-refractory to a PI and an immunomodulatory agent.

Read about what the Democratic candidates for president would do to change the healthcare system in the U.S.

FDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.

FDA approved Yondelis (trabectedin), by Janssen Biotech for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.

FDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.

Sarilumab, an investigational, human antibody against the IL-6 receptor, is highly effective in the difficult-to-treat TNF-IR population in rheumatoid arthritis (RA), according to data presented during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.

Managed Healthcare Executive has sorted through the platforms of the Republicans running for president to tell you where they stand on healthcare issues.

A new Urban Institute study looks at the availability of antidepressants in marketplace insurance plans.

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.

The Food and Drug Administration last week approved Genvoya, marketed by Gilead Sciences, to treat HIV-1 infection.

CMS recently released 2016 Star Rating data, and the news is not good for many Medicare plans, particularly for standalone Part D prescription drug plans.

Payers are in the strongest-position to activate the transition to value-based management models, but they must improve collaboration with providers.

The risk corridor program was intended to subsidize losses for care for expensive new patients brought in by the ACA, but it's not matching up to reality.

FDA has approved talimogene laherparepvec (Imlygic, Amgen) for the treatment of unresectable melanoma lesions.

An important question is whether improvements in technology can make better control accessible to patients who are not currently good candidates for insulin pumps.